Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Q4 2025 Earnings Presentation
20 slides from Cantargia Ab's earnings presentation, Feb 20, 2026
Slide 1: Year-End Report 4th Quarter & Full Year 2025
Year-End Report 4th Quarter & Full Year 2025 February 20, 2026 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Year-End Report 2025
YEAR-END REPORT 2025 Hilde Steineger Patrik Renblad Chief Executive Officer Chief Financial Officer
Slide 4: Events in the Fourth Quarter and After the Period
Events in the Fourth Quarter and After the Period Significant Events in the Fourth Quarter 2025 • Dr. Wolfram Dempke was appointed Chief Medical Officer. • The analysis of overall survival results from the Phase 1b/2 TRIFOUR study evaluating nadunolimab in triple-negative breast cancer (TNBC), showe
Slide 5: Strategic Focus & Pipeline
STRATEGIC FOCUS & PIPELINE
Slide 6: Cantargia: Redefining Cancer & Inflammation Therapy
Cantargia: Redefining Cancer & Inflammation Therapy Global Leader in IL1RAP Targeting Nadunolimab Pivotal trial ready in PDAC Strong Corporate Position Oncology FDA Fast Track Designation Otsuka deal: → Otsuka to develop and commercialize CAN10 following acquisition with upfront of $33 million and C
Slide 7: IL1RAP Pipeline supported by Unique Platform
IL1RAP Pipeline supported by Unique Platform IND Asset Target Indication Discovery Phase 1 Phase 2 Phase 3 Partner Enabling Proprietary Pipeline PDAC* Nadunolimab IL1RAP NSCLC CAN14 IL1RAP BsAb** Autoimmune diseases New development programs*** through CANxx unique IL1RAP platform Strategic Partnersh
Slide 8: Key Highlights from 2025
KEY HIGHLIGHTS FROM 2025
Slide 9: Overall Conclusions for 2025
Overall Conclusions for 2025 → A major strategic validation through the Otsuka acquisition of CAN10 → Significantly improved financial position → Continued development of nadunolimab, with FDA Fast Track Designation in PDAC patients with high IL1RAP expression → Strengthening of our IL1RAP technolog
Slide 10: Nadunolimab IIT Studies
NADUNOLIMAB IIT STUDIES
Slide 11: Ongoing Investigator-Initiated Trials with nadunolimab
Ongoing Investigator-Initiated Trials with nadunolimab Study Disease Combination therapy Number of Status NCT-number patients Leukemia* AML/MDS Azacitidine and/or venetoclax 40 Recruiting NCT06548230 Colorectal** MSS CRC Toripalimab (anti-PD-1) 24 Recruiting NCT07281716 AML - Acute Myeloid Leukemia;
Slide 12: Combining nadunolimab with Immunotherapy in Patients with metastatic MSS CRC
Combining nadunolimab with Immunotherapy in Patients with metastatic MSS CRC → The clinical study at Mount Sinai aims to investigate the combination of nadunolimab and immune checkpoint inhibitor (ICI) therapy in up to 24 patients with chemotherapy-refractory metastatic microsatellite stable (MSS) c
Slide 13: Financial Results
FINANCIAL RESULTS
Slide 14: Summary of Fourth Quarter Profit & Loss
Summary of Fourth Quarter Profit & Loss MSEK Quarter 4 2025 8.0 -36.4 -28.4 -32.3 -4.0 Revenues Operating Expenses Operating Results Net Financial Items Loss of the Period Earnings per share: -0.13 SEK 14
Slide 15: Full Year Profit of 147 MSEK
Full Year Profit of 147 MSEK MSEK Full Year 2025 -162.6 316.7 -7.1 154.1 147.0 Revenues Operating Expenses Operating Result Net Financial Items Profit for the Period Earnings per share: 0.59 SEK 15
Slide 16: Operating Expenses in the Quarter and Year-to-Date
Operating Expenses in the Quarter and Year-to-Date 168.6 162.6 132.8 40.7 R&D 153.8 36.4 R&D 36.6 32.6 29.8 Admin&Other 4.1 3.8 Admin&Other 14.8 2024 Q4 2025 Q4 2024 2025 Q4 2025 16
Slide 17: Cash Flow and Cash Position
Cash Flow and Cash Position MSEK Operating Cash Flow 339 SEK -53m (Q4, 2024: SEK -26.3m) 282 Available funds SEK 282m 140 (December 31, 2024: SEK 33m + SEK 107m in proceeds) 104 107 82 Cash Runway Current available funds are expected to fund… 33 • Ongoing commitments on nadunolimab (but not a pivota
Slide 18: Closing Remarks and Q&A
CLOSING REMARKS AND Q&A
Slide 19: A Global Leader in IL1RAP Antibody Development
A Global Leader in IL1RAP Antibody Development Potential to become best-in-class in 1L PDAC: Lead Candidate Nadunolimab ready to start pivotal trials on the back of outstanding efficacy and safety POC results, especially in high IL1RAP-expressing tumors; FDA Fast Track and Orphan Drug designations s
Slide 20: Questions!
QUESTIONS!